$2.84 -0.43 (-13.15%)

SES AI Corporation (SES)

SES AI Corporation (SES) is a technology company focusing on the development and deployment of artificial intelligence solutions. The company specializes in creating AI-driven products and services aimed at enhancing efficiency, automation, and data analytics across various industries. SES AI aims to leverage advanced machine learning and data processing techniques to deliver innovative solutions for its clients.

🚫 SES AI Corporation does not pay dividends

Company News

Why SES AI Stock Jumped 75% This Week
The Motley Fool • Neha Chamaria • October 10, 2025

SES AI's stock jumped 77.7% this week after announcing the launch of Molecular Universe 1.0, an advanced AI software for battery material discovery. The company aims to generate recurring revenue through software subscriptions and expects significant revenue growth this year.

WAVE Consortium Holds Inaugural Working Group Meeting to Advance SATCOM Virtualization and Interoperability
GlobeNewswire Inc. • Wave Consortium • November 11, 2024

The WAVE Consortium held its first working group meeting, focused on advancing virtualization and interoperability in the satellite communication (SATCOM) industry. The group aims to establish open standards, enable virtualization and automation, and drive innovation in the SATCOM ecosystem.

SES AI Corp's chief science officer sells shares worth over $29k By Investing.com - Investing.com
Investing.com • Investing.Com • July 2, 2024

SES AI Corp's Chief Science Officer, Gan Hong, sold 25,000 shares of Class A Common Stock for around $29,220 under a pre-arranged trading plan. The company has been making progress in electric vehicle and urban air mobility battery technologies, but is facing financial challenges with losses per share and a significant stock price decline.

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga • Avi Kapoor • April 15, 2024

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms. Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. Here are...

Zacks Industry Outlook Highlights Carrier Global, SES AI and Bel Fuse
Zacks Investment Research • Zacks Equity Research • August 31, 2023

Carrier Global, SES AI and Bel Fuse are part of the Zacks Industry Outlook article.